All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Early health technology assessment of diagnostic cardiology technology for reperfusion VF prediction of STEMI patients indicated for PCI

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21460%2F25%3A00379261" target="_blank" >RIV/68407700:21460/25:00379261 - isvavai.cz</a>

  • Result on the web

    <a href="https://doi.org/10.1007/s12553-024-00933-9" target="_blank" >https://doi.org/10.1007/s12553-024-00933-9</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1007/s12553-024-00933-9" target="_blank" >10.1007/s12553-024-00933-9</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Early health technology assessment of diagnostic cardiology technology for reperfusion VF prediction of STEMI patients indicated for PCI

  • Original language description

    Purpose The study deals with eHTA of new technology for STEMI patients indicated for PCI treatment, which contains diagnostic of rVF risks and medication to prevent rVF in at-risk patients above standard approved procedure. Due to the recommended medication procedure for STEMI patients with identified high rVF risks during PCI and its effectiveness have not been established the goal is to find out what level of medication effectiveness which will be sufficient for the cost-effectiveness of the new technology. Methods Scenarios where the effectiveness of rVF protecting medication administered to predisposed STEMI patients undergoing PCI varies from 5 to 95% were analyzed. Cost-effectiveness was evaluated by the CEA. Results The determined minimum effectiveness of rVF protecting medication to achieve the technology and procedure cost-effectiveness is 7.54%. Even if medication efficacy is at least 39.58%, the technology is “dominant” and the ICER is in the South-east [SE] quadrant. Conclusions Cost-effectiveness analysis show that for all scenarios modeled, except the 5% medication effectiveness scenario, the technology appears to be cost-effective. so such new technology will probably be very attractive for investors.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    20601 - Medical engineering

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2025

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Health and Technology

  • ISSN

    2190-7188

  • e-ISSN

    2190-7196

  • Volume of the periodical

    15

  • Issue of the periodical within the volume

    2

  • Country of publishing house

    DE - GERMANY

  • Number of pages

    9

  • Pages from-to

    377-385

  • UT code for WoS article

    001390194500001

  • EID of the result in the Scopus database

    2-s2.0-105002994472